Tech Company Financing Transactions
LimmaTech Biologics Funding Round
LimmaTech Biologics closed a $3 million Series A funding round on 2/1/2024. Backers included Tenmile and private investors.
Transaction Overview
Company Name
Announced On
2/1/2024
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Series A
Investors
Tenmile (Lead Investor)
Proceeds Purpose
The company intends to use the funds to further advance its proprietary platform and to accelerate the preclinical and clinical development of its vaccine candidate pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Grabenstrasse 3
Schlieren, 8952
CH
Schlieren, 8952
CH
Phone
Website
Email Address
Overview
LimmaTech was founded in 2015 as a spin-off from GlycoVaxyn. We are applying our deep expertise in engineering complex carbohydrate molecules to develop next-generation vaccines to prevent life-threatening diseases. Our proprietary pipeline is focused on diseases with emerging antimicrobial resistance (AMR).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Franz Haas
Chief Financial Officer
Paul Wolfrom
Co-Founder
Michael Kowarik
Browse more venture capital transactions:
Prev: 2/1/2024: Sentify venture capital transaction
Next: 2/1/2024: AnBogen Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs